The pharmacological management of erectile dysfunction – Update 2016
South African Family Practice
| Field | Value | |
| Title | The pharmacological management of erectile dysfunction – Update 2016 | |
| Creator | Marais, André | |
| Description | Erectile dysfunction (ED) is a trivial condition with a prevailing incidence worldwide. Phosphodiesterase-5 inhibitors (PDE-5) have revolutionised the treatment of ED and are regarded as one of the most successful drug groups in modern medicine. Generally PDE-5 inhibitors are well tolerated and the incidence of side-effects is low, however a small percentage of individuals experience headache, flushing and abdominal discomfort, resulting in discontinuation of therapy. This has led to the development of second generation PDE-5 inhibitors, displaying more selectivity for the PDE-5 enzyme thereby reducing treatment interruption and improving compliance. Several other treatment modalities, including testosterone replacement therapy and prostaglandin administration are available for resistant or failed first-line treatment. This review provides an update on the current, and future, available drugs used in the management of ED. | |
| Publisher | AOSIS | |
| Date | 2016-08-04 | |
| Identifier | 10.4102/safp.v58i4.4521 | |
| Source | South African Family Practice; Vol 58, No 4 (2016): July/August; 10-14 2078-6204 2078-6190 | |
| Language | eng | |
| Relation |
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:
https://safpj.co.za/index.php/safpj/article/view/4521/5371
|
|
ADVERTISEMENT
